[PDF] All Wales Medicines Strategy Group, National Prescribing Indicators 2016–2017

Source:
All Wales Medicines Strategy Group - AWMSG
Publisher:
All Wales Medicines Strategy Group (AWMSG)
Publication date:
01 February 2016

Abstract

This report has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG) and the All Wales Therapeutics and Toxicology Centre (AWTTC), and has subsequently been endorsed by the All Wales Medicines Strategy Group (AWMSG).The 2016-17 NPIs introduce two new NPIs: Lipid-regulating medicines: Items of bile acid sequestrants, fibrates, nicotinic acid and omega-3 fatty acid compounds (BNF 2.12 sub-set) as a percentage of total lipid-regulating items; and gabapentin and pregabalin use.  Two previous NPIs are retired: Lipid-regulating medicines: Items of LAC statins as a percentage of all statin, ezetimibe and simvastatin/ezetimibe combination prescribing; and Opioids: Items of morphine as a percentage of strong opioid prescribing.